Literature DB >> 29563518

Dietary butyrate glycerides modulate intestinal microbiota composition and serum metabolites in broilers.

Xiaojian Yang1, Fugui Yin1,2, Yuhui Yang3, Dion Lepp1, Hai Yu1, Zheng Ruan4, Chengbo Yang5, Yulong Yin2,4,6, Yongqing Hou6, Steve Leeson7, Joshua Gong8.   

Abstract

Butyrate can modulate the immune response and energy expenditure of animals and enhance intestinal health. The present study investigated changes in the intestinal microbiota composition and serum metabolites of young broilers in response to 3,000 ppm butyrate in the form of butyrate glycerides (BG) via pyrosequencing of bacterial 16S rRNA genes and nuclear magnetic resonance (NMR). The dietary treatment did not affect the alpha diversity of intestinal microbiota, but altered its composition. Thirty-nine key operational taxonomic units (OTUs) in differentiating cecal microbiota community structures between BG treated and untreated chickens were also identified. Bifidobacterium was, in particular, affected by the dietary treatment significantly, showing an increase in not only the abundance (approximately 3 fold, P ≤ 0.05) but also the species diversity. The (NMR)-based analysis revealed an increase in serum concentrations of alanine, low-density and very low-density lipoproteins, and lipids (P ≤ 0.05) by BG. More interestingly, the dietary treatment also boosted (P ≤ 0.05) serum concentrations of bacterial metabolites, including choline, glycerophosphorylcholine, dimethylamine, trimethylamine, trimethylamine-N-oxide, lactate, and succinate. In conclusion, the data suggest the modulation of intestinal microbiota and serum metabolites by BG dietary treatment and potential contribution of intestinal bacteria to lipid metabolism/energy homeostasis in broilers.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29563518      PMCID: PMC5862971          DOI: 10.1038/s41598-018-22565-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

Butyrate, a product of bacterial fermentation of dietary carbohydrates in the digestive tract, plays a vital role in maintaining intestinal health and homeostasis as well as ameliorating the metabolic and immune status in animals. It is a preferred energy-providing substrate over glucose and glutamine for colonic epithelial cells and may count for approximately 70% of the total energy consumption of the colonocyte[1,2]. Butyrate can increase cell proliferation in the small and large intestine, and enhance the intestinal barrier by facilitating tight junction assembly[3,4]. Our recent study also indicates that butyrate can induce energy expenditure and lipid catabolism by regulating the expression of genes that have a role in the reduction of synthesis, storage, transportation, and secretion, and in the increase of oxidation of lipids and fatty acids in 3-week-old broiler chickens[5]. At the systemic circulation level, butyrate beneficially reduces the concentrations of total circulating triglycerides and cholesterol in broilers[5,6]. In addition, it has immuno-modulatory activities via histone deacetylase inhibition[7-9]. For example, butyrate induces the gene expression of antimicrobial host defense peptides, including defensins and cathelicidins in chickens[10], as well as modulates the expression and release of anti- and pro-inflammatory cytokines in broilers[11] and fish[12]. Nonetheless, there is limited knowledge about the effects of butyrate on the ecology of the intestinal microbiota, the whole profile of serum metabolites, and the links between them. Nuclear magnetic resonance (NMR)-based metabolomics analysis[13,14] is a tool that can be used to assess the functionalities of nutrients via the simultaneous measurement of multiple metabolites in complex organisms, and therefore to explore how metabolic balances are disturbed by dietary nutrient interventions[15]. The advance of high throughput DNA sequencing techniques and data analyses allows comprehensive studies of the ecology of intestinal microbiota[16]. The objective of the present study was, therefore, to determine the changes in the intestinal microbiota and serum metabolites as well as their potential links in response to dietary treatment of butyrate (in the form of butyrate glycerides, BG) using a combined approach of NMR-based metabolomics analysis and metagenomics techniques including pyrosequencing of bacterial 16S rRNA genes, quantitative PCR (qPCR) assays, and NMR-based metabolomics analysis.

Results

Sequence analysis and quality filtering

Twelve samples per segment were used for pyrosequencing of bacterial 16S rRNA genes. After denoising, removal of chimeras, and filtering low quality sequences, the average number of DNA sequences per ileal digesta sample was 13,513 ± 2,022 with an average sequence length of 372 nucleotides. The sequences were collapsed into 489 operational taxonomic units (OTUs) at the 97% identity level. In the cecal digesta samples, the average number of sequences was 11,375 ± 2,014 per sample with an average sequence length of 383 nucleotides after the filtering. The sequences were grouped into 971 OTUs and deposited with the GenBank accession numbers MG773882 - MG774333.

Effects of dietary butyrate glycerides on the ileal microbiota

To determine the effects of dietary treatment with butyrate glycerides on the ileal microbiota, the within-community (α) diversity was firstly assessed. The rarefaction curves including the plots of Shannon index, Chao1 index, phylogenetic distance (PD), and number of unique OTUs approached a plateau as sequence numbers increased (Fig. S1), indicating that the sequence depth was sufficient for capturing the majority of OTUs in the ileal samples. No significant treatment effects on the diversity of ileal microbiota were observed (P > 0.05). The similarities between pairs of microbial communities (β-diversity) were also examined using a principal coordinate analysis (PCoA) based on the unweighted UniFrac distance (Fig. 1A). No distinguishable clustering of the samples appeared to be evident between the control and treatment group (Fig. 1B). This was further confirmed by the analysis of similarities (ANOSIM) (R = 0.02, P = 0.42).
Figure 1

Effects of butyrate glycerides on the β-diversity of ileal microbiota. Two dimensional plots of PCoA are based on the unweighted UniFrac distance (B). ANOSIM is based on the unweighted UniFrac distance between microbial communities (C). BD: basal diet; BG: BD supplemented with butyrate glycerides.

Effects of butyrate glycerides on the β-diversity of ileal microbiota. Two dimensional plots of PCoA are based on the unweighted UniFrac distance (B). ANOSIM is based on the unweighted UniFrac distance between microbial communities (C). BD: basal diet; BG: BD supplemented with butyrate glycerides. All OTUs with abundance ≥0.005% were taxonomically assigned with the Ribosomal Database Project (RDP) classifier at 80% confidence threshold. More than 99% of the ileal sequences were assigned to bacterial phyla. Firmicutes was the most predominant phylum (>90%) followed by Proteobacteria (4%) and Cyanobacteria (2%) (Fig. S2). At the family level, Clostridiaceae was predominant (>49%), followed by Lactobacillaceae (>21%), Enterobacteriaceae (>3%), Ruminococcaceae (>2%), and Lachnospiraceae (>1%). Over 99% of the sequences from family Clostridiaceae could not be classified further to the genus level, while Lactobacillus was the only genus found in family Lactobacillaceae. Analyses using the Metastats method[17] revealed no significant difference (P>0.05) in the relative abundance (normalized as percentage of total number of sequences) of microbiota composition between the control and treatment group except for more than 10-fold reduction of family Bacillaceae/genus Bacillus (P ≤ 0.05) in BG-treated chickens.

Effects of dietary butyrate glycerides on the cecal microbiota

The rarefaction curves showing the α-diversity of cecal microbiota are displayed in Fig. S1. The majority of OTUs in the cecal samples appeared to be captured. Similarly, there was no significant difference in the diversity of cecal microbiota between the control and treatment group (P > 0.05). The microbial community structures between the control and treatment group (β-diversity) were compared using the PCoA of unweighted UniFrac distance. Birds from the control group were distinctly separated from those in the BG group (Fig. 2A). The first and second axis of the PCoA explained 12.50% and 25.95% variation in microbial diversity, respectively. Further analysis with ANOSIM revealed a significant difference (R = 0.57, P = 0.006) in microbial communities of cecal microbiota between the two groups (Fig. 2B).
Figure 2

Effects of butyrate glycerides on the β-diversity of cecal microbiota. Two dimensional plots of PCoA are based on the unweighted UniFrac distance (B). ANOSIM is based on the unweighted UniFrac distance between microbial communities (C). BD: basal diet; BG: BD supplemented with butyrate glycerides.

Effects of butyrate glycerides on the β-diversity of cecal microbiota. Two dimensional plots of PCoA are based on the unweighted UniFrac distance (B). ANOSIM is based on the unweighted UniFrac distance between microbial communities (C). BD: basal diet; BG: BD supplemented with butyrate glycerides. More than 90% of the cecal sequences were assigned to bacterial phyla. Of these sequences, more than 85% were classed to the family level, and 44% to the genus level. The cecal microbiota was dominated by Fimicutes (>76%) followed by Bacteroidetes (>11%) Tenericutes (>1%), and Proteobacteria (>0.3%), in addition to more than 6% unclassified bacteria (Fig. S2). At the family level, Ruminococcaceae was the predominant group (>40%) followed by Lachnospiraceae (>19%), Bacteroidaceae (>11%), Clostridiaceae (>4%), and Catabacteriaceae (>1%). At the genus level, Bacteroides accounted for more than 11% of bacterial population, followed by Oscillospira (>7%), Faecalibacterium (>7%), Clostridium (>3%), and Ruminococcus (>3%). Some sequences from order Clostridiales and families Ruminococcaceae and Lachnospiraceae could not be further classified to the genus level, which accounted for more than 7%, 23%, and 12% of the population, respectively. Analyses using the Metastats method[17] revealed that dietary treatment with BG resulted in a decrease in the relative abundance of class Mollicutes (6-fold, P ≤ 0.05), and genera Eubacterium (2-fold, P ≤ 0.05), Subdoligranulum (20-fold, P ≤ 0.05), and Holdemania (0.03% vs. absent, P ≤ 0.05). On the contrary, the supplementation of BG led to a 3-fold increase (P ≤ 0.05) of genus Anaerotruncus. No differences (P>0.05) in relative abundance were noticed for the remaining taxonomic groups at different levels. To identify key OTUs in the discrimination of microbial community structures of cecal microbiota between the control and treatment groups, sparse partial least squares discriminant analysis (SPLS-DA) was conducted. The SPLS-DA yielded a correct classification rate of 85% for the cecal samples. Thirty-nine OTUs were identified by SPLS-DA as the key variables in the differentiation of cecal microbial profiles of the two groups (Table 1). Among the 39 OTUs, the abundance of 14 OTUs was enhanced in the cecal samples from BG-treated birds, among which 8 OTUs belonged to genera Anaerotruncus (1), Bacteroides (5), Blautia (1), and Lactobacillus (1), and 6 OTUs belonged to families Lachnospiraceae (4), Ruminococcaceae (1), and Clostridiales Family XIII Incertae Sedis (1). On the contrary, the abundance of 25 OTUs was increased in the cecal samples from birds in the control group, among which 9 belonged to genera Bacteroides (2), Clostridium (1), Oscillospira (4), and Subdoligranulum (2); 12 OTUs belonged to families Ruminococcaceae (10) and Lachnospiraceae (2); 3 OTUs belonged to order Clostridiales; and 1 OTU was unclassified. The heat map of the 39 OTUs is shown in Fig. 3.
Table 1

Key OTUs in discriminating cecal microbial profiles between BD and BG-fed chickensa.

OTU numberRelative abundance (%) Mean ± SE (n = 6)P-valueAnnotation
BDbBG
80.328 ± 0.0240.121 ± 0.0170.006order: Clostridiales
810.698 ± 0.0470.012 ± 0.0040.0001family: Ruminococcaceae
910.011 ± 0.0020 ± 00.012family: Ruminococcaceae
1820.007 ± 0.0020.093 ± 0.0100.002genus: Lactobacillus
2050.051 ± 0.0100.261 ± 0.0330.013family: Lachnospiraceae
2070.013 ± 0.0010 ± 00.001genus: Oscillospira
2420.019 ± 0.0030 ± 00.010order: Clostridiales
2930.014 ± 0.0020.062 ± 0.0030.0002family: Ruminococcaceae
3600.063 ± 0.0110.185 ± 0.0160.013family: Lachnospiraceae
3620.705 ± 0.1020.004 ± 0.0000.007family: Lachnospiraceae
4130.110 ± 0.0100.029 ± 0.0110.004family: Ruminococcaceae
4150.021 ± 0.0040.121 ± 0.0110.002genus: Bacteroides
4173.263 ± 0.3070.425 ± 0.1090.002family: Ruminococcaceae
4310.053 ± 0.0090 ± 00.012genus: Bacteroides
4360.155 ± 0.0230 ± 00.007family: Ruminococcaceae
4490.187 ± 0.0210 ± 00.001genus: Oscillospira
4593.334 ± 0.1526.969 ± 0.5490.010genus: Bacteroides
4700.025 ± 0.0040.09 ± 0.0070.002genus: Bacteroides
4770.049 ± 0.0040 ± 00.0003family: Lachnospiraceae
5050.746 ± 0.1080 ± 00.006genus: Subdoligranulum
5080.255 ± 0.0240 ± 00.001genus: Bacteroides
6030.119 ± 0.0110.002 ± 0.0010.001genus: Clostridium
6050.260 ± 0.0330.871 ± 0.0630.002genus: Anaerotruncus
6080.016 ± 0.0020 ± 00.006family: Ruminococcaceae
6572.281 ± 0.3320 ± 00.007genus: Oscillospira
7030 ± 00.093 ± 0.0130.006famliy: ClostridialesFamilyXIII.IncertaeSedis
7810.009 ± 0.0010 ± 00.008family: Ruminococcaceae
7890.019 ± 0.0020 ± 00.001family: Lachnospiraceae
7940.001 ± 0.0000.007 ± 0.0010.107family: Lachnospiraceae
8030.106 ± 0.0120.016 ± 0.0050.007family: Ruminococcaceae
8060.169 ± 0.0150.645 ± 0.0460.001genus: Bacteroides
8120.030 ± 0.0030.006 ± 0.0020.008order: Clostridiales
8140.005 ± 0.0010 ± 00.128Unclassified
8340.006 ± 0.0010.031 ± 0.0040.008genus: Bacteroides
8520.038 ± 0.0050 ± 00.003genus: Oscillospira
8530.079 ± 0.0090 ± 00.002family: Ruminococcaceae
8750.400 ± 0.0540.021 ± 0.0040.006genus: Subdoligranulum
9330.013 ± 0.0020.115 ± 0.0130.004genus: Blautia
9450.141 ± 0.0100 ± 00.0001family: Ruminococcaceae

aIdentified by SPLS-DA analysis.

bBD: basal diet; BG: BD diet supplemented with butyrate glycerides.

Figure 3

Heat map of the key OTUs identified in the cecal microbiota. The OTUs are identified by SPLS-DA as key variables for the differentiation of microbial profiles in the cecal microbiota of BG-treated and untreated (BD) groups. Percentage composition based on the 16S rRNA sequence is indicated by the color intensity. N = 6; 1, 2, 3, 4, 5, 6: number of the birds. The color key value indicates relative abundance of an OUT expressed as percentage of total number of sequences for an individual bird.

Key OTUs in discriminating cecal microbial profiles between BD and BG-fed chickensa. aIdentified by SPLS-DA analysis. bBD: basal diet; BG: BD diet supplemented with butyrate glycerides. Heat map of the key OTUs identified in the cecal microbiota. The OTUs are identified by SPLS-DA as key variables for the differentiation of microbial profiles in the cecal microbiota of BG-treated and untreated (BD) groups. Percentage composition based on the 16S rRNA sequence is indicated by the color intensity. N = 6; 1, 2, 3, 4, 5, 6: number of the birds. The color key value indicates relative abundance of an OUT expressed as percentage of total number of sequences for an individual bird.

Effect of dietary butyrate glycerides on Bifidobacterium and butyrate-producing bacteria

In the present study, genus Bifidobacterium was not detected in the digesta samples by the PCR primers universal to eubacterial 16S rRNA genes during pyrosequencing, which possibly resulted from a base-pair mismatch or low amplification efficiency of PCR primers as reported previously[18,19]. To investigate the effects of BG supplementation on the population of Bifidobacterium, a pair of PCR primers[20] specific to the xylulose-5-phosphate⁄fructose-6-phosphate phosphoketolase (xfp) gene, which is characteristic of the Bifidobacterium genus[21], were used for subsequent sequence analysis and qPCR assays. Approximately 5,000 bifidobacterial sequences per sample with an average length of 309 nucleotides were obtained from pyrosequencing. Among the sequences identified at the species level by comparison of the gene sequence similarities[21], 46.9%, 49.9%, and 3.2% were assigned to B. gallinarum, B. saeculare, and B. pullorum, respectively, in the cecal samples from BG-treated birds. B. saeculare was the only Bifidobacterium species identified in the control group. The effects of dietary treatment with BG on the relative abundance of Bifidobacterium and some groups of butyrate-producing bacteria were also assessed by qPCR assays. Supplementation of BG increased the Bifidobacterium abundance in the cecal samples by approximately 3 fold (Table 2). However, the supplementation had no effects (P > 0.05) on the abundance of Clostridial cluster IV and cluster XIVa that harbour butyrate-producing bacteria[22,23]. In addition, no significant difference (P>0.05) in the abundance of the gene encoding butyryl-CoA: acetate CoA transferase in the acetyl-CoA pathway, which is the most prevalent in bacterial production of butyrate[24], was detected in the cecal samples between the control and treatment group.
Table 2

Fold changes in the abundance of selected cecal bacterial groups determined by qPCR.

BacteriumFold change (95% confidence interval, n = 6)P-value
BDaBG
Butyryl-CoA:acetate CoA transferase11.19 (0.55–2.58)0.6162
Colostridial cluster IV11.06 (0.47–2.36)0.8706
Colostridial cluster XIVa11.38 (0.84–2.25)0.1684
Bifidobacterium (genus)12.84 (1.58–5.10)0.0026

aBD: chickens on a basal diet. BG: chickens fed BD diet supplemented with butyrate glycerides.

Fold changes in the abundance of selected cecal bacterial groups determined by qPCR. aBD: chickens on a basal diet. BG: chickens fed BD diet supplemented with butyrate glycerides.

Effects of dietary butyrate glycerides on serum metabolites

A total of 42 metabolites were unambiguously identified by the 1H-NMR spectroscopic analysis in the samples from both treatments, and their chemical shifts, peak multiplicity, and the corresponding 1H NMR signal multiplicities were determined (Table 3). The assignment of metabolites was based on previous reports[25-27]. The spectra of the serum samples contained resonances from amino acids, organic acids, albumin, lipids, unsaturated lipids, choline, and creatine. Multivariate statistical analysis was used to detect subtle treatment-related metabolic differences[14,28]. Principal component analysis (PCA) was performed on the 1H NMR spectra of serum samples between BG-treated and untreated birds. The PCA score plot of the 1H NMR serum data is shown in Fig. 4A, with each point representing an individual spectrum of a sample showing separation of BG-treated birds from the untreated chicks. Partial least squares discrimination analysis (PLS-DA)-based profiling was also employed to explore the intrinsic differences between BG- and BD-fed groups. The samples from different groups were separated and classified into two distinct clusters as shown in the PLS-DA score plot (Fig. 4B). The model parameters (R2X = 0.563, R2Y = 0.932, Q2 = 0.608) and the validated model (permutation number: 200) indicated no over fitting (Fig. 4C). All of the results indicated the existence of differences between the two groups. Furthermore, the spectral datasets were analyzed by orthogonal partial least squares discriminant analysis (OPLS-DA). The BG-fed group was clearly separated from the BD-fed chickens as shown in the OPLS-DA scores plot (Fig. 4D) and by permutation tests and ANOVA of the cross-validated residuals (CV-ANOVA) (P ≤ 0.05). The metabolites responsible for a significant contribution to the separation of two groups are indicated in the corresponding S-plot, including low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), lipids, lactate, alanine, succinate, dimethylamine, trimethylamine, choline, glycerophosphorylcholine (GPC), and trimethylamine-N-oxide (TMAO) that are numbered from 1 to 10 in Fig. 4E. The VIP statistic of the first principal component of OPLS-DA model (threshold ≥ 1), together with the P-value of the t-test (threshold ≤ 0.05), was used for selecting significant variables responsible for groups separation. Dietary supplementation of BG was accompanied by increased (P ≤ 0.05) concentrations of serum lactate, alanine, LDL/VLDL, and lipids. More interestingly, the concentrations of intestinal bacteria-derived metabolites also increased (P ≤ 0.05), including choline, GPC, dimethylamine, trimethylamine, TMAO and succinate (Table 4).
Table 3

Assignments of serum metabolites.

KeyMetaboliteMoietyδ1H (ppm) & multiplicity
1LDL/VLDLCH3, CH2CH2C= 0.88(m), 1.28(m)
2IsoleucineγCH3, δCH30.94(t), 1.01(d)
3LeucineαCH, δCH3, δCH30.91(d), 0.96(d), 3.72(t)
4ValineαCH3, βCH, γCH30.99(d), 1.04(d)
5EthanolCH2, CH33.65(q), 1.18(t)
6β-HydroxybutyrateγCH31.22(d)
7Lipids (triglycerides and fatty acids)CH3(CH2)n, (CH2)n,CH2*CH2CO, CH2-C=CCH2-C=O, CH-O-CO1.22 (m), 1.29 (m),1.58(m), 2.04(m)2.24(m), 2.75(m)
8ThreonineαCH, βCH, γCH31.32(d), 4.25(m), 3.58(d)
9LactateαCH, βCH31.33(d), 4.11(q)
10AlanineαCH, βCH33.77(q), 1.48(d)
11LysineαCH, βCH2, γCH2, δCH23.77(t), 1.89(m), 1.73(m)
12AcetateCH2-C=O1.92(s)
13GlycoproteinCH3-C=O2.05(s), 2.08(m), 2.15(s)
14GlutamateαCH, βCH2, γCH23.75(m), 2.08(m), 2.37(m)
15PyruvateCH32.37(s)
16Succinateα, βCH22.41(s)
17GlutamineαCH, βCH2, γCH23.68(t), 2.15(m), 2.45(m)
18MethylamineCH32.54(s)
19DimethylamineCH32.71(s)
20TrimethylamineCH32.92(s)
21AlbuminLysyl-CH23.02(s)
22CreatineN-CH3, CH23.04(s), 3.93(s)
23CreatinineCH3, CH23.05 (s), 4.05(s)
24CholineN-(CH3)3, αCH2, βCH23.20(s), 4.05(t), 3.51(t)
25GPCN-(CH3)3, OCH2, NCH23.22(s), 4.32(t), 3.51(t)
26TMAOCH33.26(s)
27TaurineN-CH2, S-CH23.27(t), 3.43(t)
28BetaineCH3, CH23.28(s), 3.90(s)
29ProlineβCH2, γCH2, δCH22.02–2.33(m), 2.00(m), 3.35(t)
30AcetoacetateCH3, CH22.29(s), 3.49(s)
31GlycineCH23.56(s)
32OrnithineCH2, αCH3.80(s), 3.79(t)
33Myo-Inositol5-CH, 4, 6-CH, 2-CH3.30(t), 3.63(t), 4.06(t)
34β-Glucose2-CH, 1-CH3.25(dd), 4.65(d)
35α-Glucose1-CH5.24(d)
36Unsaturated lipids = C-CH2-C= ,-CH=CH-5.19(m), 5.31(m)
37FumarateCH6.52(s)
38TyrosineαCH, CH27.19(d), 6.89(d)
39Phenylalanine2, 6-CH, 3, 5-CH, 4-CH7.33(m), 7.38(m), 7.42(m)
401-Methylhistidine4-CH, 2-CH7.05(s), 7.77(s)
413-Methylhistidine4-CH, 2-CH7.00(s), 7.60(s)
42FormateCH8.45(s)

Note: GPC, Glycerophosphorylcholine; LDL, Low-density lipoprotein; VLDL, Very low-density lipoprotein; TMAO, Trimethylamine N-oxide.

Figure 4

Pattern recognition with SIMCA-P 13.0. The PCA score plot (A), PLS-DA score plot (B), PLS-DA validation plots (permutation number: 200) (C), as well as OPLS-DA score plot (D) were derived from 1H NMR serum spectra of the BG-fed group compared with BD-fed chickens. Corresponding S-plot between BG-fed and BD-fed chickens, indicating the metabolites that changed significantly (panel E): 1, LDL/VLDL; 2, lipids; 3, lactate; 4, alanine; 5, succinate; 6, dimethylamine; 7, trimethylamine; 8, choline; 9, GPC; 10, TMAO.

Table 4

Changes in relative concentrations of serum metabolites by butyrate glycerides.

No.MetaboliteChemical shift (δ)FCaVIPbChange in directionP-valuec
1LDL/VLDL0.881.493.490.013
2Lipids1.221.813.800.030
3Lactate1.342.405.410.002
4Alanine1.481.571.730.046
5Succinate2.411.791.130.040
6Dimethylamine2.712.031.310.044
7Trimethylamine2.921.962.640.035
8Choline3.202.531.300.012
9GPC3.223.091.820.006
10TMAO3.263.514.860.002

Note: GPC, Glycerophosphorylcholine; LDL, Low-density lipoprotein; VLDL, Very low-density lipoprotein; TMAO, Trimethylamine N-oxide.

aFC: fold change between BG and BD diet-fed groups.

bVariable importance in the projection (VIP ≥ 1) was obtained from OPLS-DA analysis.

cP-value determined from Student’s t-test.

↑: a relative increase in the integral value for the region containing the identified metabolite.

Assignments of serum metabolites. Note: GPC, Glycerophosphorylcholine; LDL, Low-density lipoprotein; VLDL, Very low-density lipoprotein; TMAO, Trimethylamine N-oxide. Pattern recognition with SIMCA-P 13.0. The PCA score plot (A), PLS-DA score plot (B), PLS-DA validation plots (permutation number: 200) (C), as well as OPLS-DA score plot (D) were derived from 1H NMR serum spectra of the BG-fed group compared with BD-fed chickens. Corresponding S-plot between BG-fed and BD-fed chickens, indicating the metabolites that changed significantly (panel E): 1, LDL/VLDL; 2, lipids; 3, lactate; 4, alanine; 5, succinate; 6, dimethylamine; 7, trimethylamine; 8, choline; 9, GPC; 10, TMAO. Changes in relative concentrations of serum metabolites by butyrate glycerides. Note: GPC, Glycerophosphorylcholine; LDL, Low-density lipoprotein; VLDL, Very low-density lipoprotein; TMAO, Trimethylamine N-oxide. aFC: fold change between BG and BD diet-fed groups. bVariable importance in the projection (VIP ≥ 1) was obtained from OPLS-DA analysis. cP-value determined from Student’s t-test. ↑: a relative increase in the integral value for the region containing the identified metabolite.

Discussion

The effects of butyrate on the intestinal microbiota of piglets and broiler chickens have been investigated previously by culture-based[29] and non-culture-based methods, such as restriction fragment length polymorphism (RFLP) and fluorescence in situ hybridization (FISH)[30,31]. Due to the limitation of the methods, limited knowledge has been generated from these studies. The use of pyrosequencing in the present study uncovered a more comprehensive picture of the intestinal microbiota composition and structure. In the current study, dietary BG treatment did not affect the diversity of ileal and cecal microbiota, but altered the microbiota composition. This suggests that BG may have reached the lower intestinal tract like the caeca, owing to the hydrophilic nature of the monoglycerides in the form of monobutyrin. Compared with the change in the ileal microbiota (only Bacillus), there were several changes to the cecal bacteria, including to the class Mollicutes and genera Eubacterium, Subdoligranulum, Holdemania, Anaerotruncus, and Bifidobacterium. Many Mollicutes members cause diseases (including colitis) in humans and animals[32]. Holdemania has also been reported to be associated with unhealthy ceca and the use of antibiotics in animals[33,34]. The reduction in the abundance of Mollicutes and Holdemania in the present study suggests the beneficial effects of dietary BG treatment on chicken intestinal health. According to Bergey’s Manual of Systematic Bacteriology (the second edition), the genera Subdoligranulum[35], Eubacterium[36], and Anaerotruncus[37] contain 1 (Subdoligranulum variabile), 44 (Eubacterium), and 1 (Anaerotruncus colihominis) species, respectively, among which many can produce butyric and lactic acids[22,38]. The decrease in the Subdoligranulum population by BG supplementation in the present study implies a functional suppression by butyrate released from BG, possibly as the result of feedback from the high level of butyrate in the chicken cecum. One striking observation in the present study is the effect of BG on the significant increase of Bifidobacterium in both diversity and abundance, as revealed by amplification of the xfp gene with both pyrosequencing analysis and qPCR assays. Bifidobacterium spp. are well-recognized probiotic bacteria with a wide spectrum of benefits[39]. Thus, the supplementation of BG likely promotes chicken health and well-being. Recently, we reported the modulation of energy and lipid metabolism in young broiler chickens at the age of three weeks by dietary BG treatment[5]. There was up-regulation of genes involved in the biological processes for the reduction of synthesis, storage, transportation and secretion of lipids in the jejunum, and for the enhancement of the oxidation of ingested lipids and fatty acids in the liver. In particular, the gene expression of transcriptional regulators of thyroid hormone responsive (THRSP) and early growth response gene-1 (EGR-1) as well as some in the peroxisome proliferator-activated receptors (PPAR) signaling pathway was significantly affected by BG. Moreover, serum triglycerides and total cholesterol were lowered in BG-fed birds. While lipoprotein lipase was decreased in the jejunum, liver and adipose of BG-fed birds, fatty acid synthase levels were lowered in the serum, liver and adipose tissue of the same birds. In animals, energy and lipid metabolism is a complex process, which is regulated by a wide array of interdependent factors, including nutrients, hormones, nuclear transcription factors, and corresponding enzymes[40,41]. A change of the profiles of circulating metabolites may thus partially reflect the effects of dietary treatments on energy and lipid metabolism. There are two pathways, through which metabolites are involved in energy catabolism, including the pyruvate (alanine) production pathway and the “energy shift” pathway[42]. Alanine is most commonly produced by reductive amination of pyruvate with the consumption of ATP[43]; the higher serum concentration of alanine in BG-fed birds in the current study indirectly indicates an increase of pyruvate consumption as well as energy expenditure[44]. Another interesting observation is the relative higher concentrations of LDL/VLDL and lipids in the BG-fed birds than those in the control group, suggesting that BG promoted the transportation of lipids; thus reducing the storage of fatty acids in peripheral tissue[14,45]. The intestinal microbiota can also affect host metabolism[46]. In the current study, dietary supplementation of BG increased the serum concentrations of choline, GPC, dimethylamine, trimethylamine, TMAO, and succinate when compared to those of control birds. These metabolites have been suggested to be derived from intestinal bacteria, particularly from Bifidobacterium, and are associated with several metabolic pathways[46]. For example, choline, dimethylamine, trimethylamine, and TMAO are mainly involved in the choline metabolic pathway to modulate lipid catabolism and glucose homeostasis[47-51]. It has been reported that major adverse cardiovascular events are normally accompanied with an increased level of TMAO[52]. It is unclear if the serum TMAO level observed in the present study was sufficient to trigger corresponding diseases in broilers. The GPC is a putative acetylcholine precursor that potentially increases growth hormone secretion and enhances fat oxidation[53]. Succinate is a key intermediate in microbial propionate synthesis[54], and is also identified as a substrate for intestinal gluconeogenesis, a biological process that improves glucose homeostasis[55]. Collectively, enhanced serum concentrations of these metabolites by BG supplementation indicate that chicken intestinal bacteria can also contribute to lipid and energy metabolism through their metabolites to benefit the host. Discovery of the relationships among the intestinal microbiota composition, microbiota-dependant metabolism, and animal performance can provide opportunities to improve food animal production. There have been studies on a link between bacterial species in the chicken intestine to the energy metabolism of broilers[56,57]. Some bacterial groups in the ileum and cecum[58,59] or feces[60] were related to feed conversion efficiency in chickens. For example, OTUs representing 26 bacterial species or phylotypes related to Lactobacillus spp., Ruminococcaceae, Clostridiales, Gammaproteobacteria, Bacteroidales, Clostridiales/Lachnospiraceae, and unclassified bacteria/clostridia in the ileum and cecum were found to be associated with feed efficiency of broiler chickens[58]. Recently, we reported that the supplementation of BG increased feeding efficiency by 10% and reduced abdominal fat deposition in 3-week-old broilers[5]. In the present study, 39 OTUs in the cecum of young birds were identified, which demonstrated changes in the relative abundance responding to BG treatment. Among these OTUs, Ruminococcaceae (18 OTUs) was the most predominant family followed by Bacteroidaceae (7 OTUs), Lachnospiraceae (6 OTUs), and order Clostridiales (5 OTUs). Only one OTU was assigned to Lactobacillus. These data support the previous observation by Torok et al.[58]. Bifidobacterium and Faecalibacterium prausnitzii are two groups of intestinal bacteria producing choline metabolites that can modulate lipid metabolism and glucose homeostasis[46], and thus possibly alter animal health status and performance. The observations on the reduction of abdominal fat deposition in broilers in our previous study, and on the increase in serum concentrations of choline metabolites and in the diversity and abundance of Bifidobacterium in the chicken intestine by BG supplementation in the present study suggest that Bifidobacterium may have contributed to the decrease of abdominal fat deposition through the influence over the production of choline metabolites.

Methods

Animals, diets, and sample collection

The protocol for the animal trial was approved by the Animal Care and Use Committee of University of Guelph (AUP No. 3176) in accordance with the Canadian Council on Animal Care’s Guidelines. The feed ingredients and levels, including both BG additives and monensin, were the same as those used in the previous study [5]. The BG additives were mono-butyrin (mono-C4) and a mixture of 30% mono-, 50% di-, and 20% triglycerides of n-butyric acid (Baby C4), commercially available from SILO (Industria Zootecnica, Florence, Italy). No antibiotics were used throughout the trial except for monensin for the purpose of coccidiosis prevention. Forty eight 1-d-old male birds (Ross 308; Stratford Chick Hatchery, Stratford, ON, Canada) were allocated equally into two dietary treatments: 1) basal diet-fed group (control), and 2) BG diet (basal diet + BG)-fed group. There were 24 birds per treatment with four birds each unit on the floor. The birds in the control group were fed a commercial diet for starter phase (0 to 20 d), while those in the BG diet-feed group consumed their assigned diet in a two phases program, namely a starter diet containing 3,000 ppm each of Mono C4 and Baby C4 from 0 to 7 d, and 3,000 ppm of Mono C4 only from 8 to 20 d. Feeding program, environmental temperature, and lighting schedules were the same as previously reported[5]. Feed and water were freely available. All the birds appeared healthy and grew well throughout the entire experimental period. On d 20, six birds were randomly selected from each treatment (one bird per cage), and approximately 4 mL blood samples were collected from the jugular vein into 5 mL heparin-free vacutainer tubes (Becton Dickinson Vacutainer Systems, Franklin Lakes, NJ, USA). Samples were centrifuged at 750 g for 10 min at 4 °C, the supernatant (serum) was immediately collected and placed into test-tubes and stored at −20 °C until a NMR-based analysis. After blood collection, the same birds (six chickens per treatment) were killed by cervical dislocation, and digesta samples from the cecum and a 10-cm-long section of the ileum (5 cm away from the ileocecal junction) of each bird were aseptically collected, and stored at −80 °C until further analysis. There were 24 digesta samples collected in total with 12 samples from each treatment (6 birds per treatment with 2 segmental digesta samples of each bird).

1H-NMR spectroscopic analysis of serum

1H-NMR spectroscopic analysis of chicken serum samples was performed by the NMR Laboratory (nmr@chemistry.mcmaster.ca) in the Department of Chemistry and Chemical Biology, McMaster University (Hamilton, Ontario, Canada). One hundred microlitres of 0.9% saline in D2O with 1 mg/ml sodium [2,2,3,3-d4]3-trimethylsilyIpropanoate (TSP-d4) was mixed with 500 µl serum in high quality 5-mm NMR tubes. 1H NMR spectra of serum were recorded on a Bruker Avance III 700 MHz NMR spectrometer (Bruker Biospin, Rheinstetten, Germany) equipped with a 5 mm QNP cryo-probe and SampleJet autosampler, and operating at a proton frequency of 700.17 MHz. A carr-Purcel-Meiboom-Gill (CPMG) spin-echo pulse sequence [recycle delay−90°− (τ–180°–τ)n–acquisition] was used to emphasize resonances from low molecular-weight metabolites[14,28,61]. 1H NMR data for each sample were acquired using 128 scans (64k data points) with a 2.5 second relaxation delay. Chemical shifts were referenced to the internal reference (TSP-d4: 0.00 ppm). 1H NMR data with water suppression using excitation sculpting with gradients were subsequently acquired using the same number of scans and time of relaxation delay as that for 1H NMR data.

Analysis of NMR data

The NMR spectra of serum samples were Fourier-transformed, phase adjusted, and baseline corrected using Mnova-6.1.1 (Mestrelab, Santiago de compostela, Spain) as previously described[14]. Chemical shifts were referenced to the internal reference (TSP-d4: 0.00 ppm). Each spectrum (δ 0.8–8.5) was segmented into contiguous segments having an equal width (0.01 ppm) and integrated over the region from equal width. The region δ 4.69–5.20 was removed to avoid the influence of the water signal. The integral of each region was determined. Resultant data sets were then imported into SIMCA-P 13.0 (Umetrics, Sweden) for multivariate statistical analysis. The PCA was applied to discern the presence of inherent similarities of spectral profiles and identify possible outliers within the dataset[62]. The PLS-DA was conducted to distinguish BG and BD diet-fed groups in a supervised manner. Parameters for model fitness (R2) and predictive ability (Q2) with leave-one-out cross validation and the response of the permutation test (200 times) needed to be used to evaluate whether the model could be established because of the small number of samples. Furthermore, a supervised pattern recognition approach known as OPLS-DA was used to improve the classification of the BG and BD diet-fed group while screening biomarkers. With an aim to discover the potential variables contributing to the differentiation, we generated an S-plot for the OPLS-DA model to define metabolites significantly contributing to the separation of the two groups. On the basis of the variable importance in the project (VIP) threshold of 1 (VIP ≥ 1.00), a number of metabolites responsible for the difference in metabolic profiles of the two groups could be obtained. In parallel, the metabolites identified by the OPLS-DA were validated at a univariate level using t-test (SPSS 17.0) with the critical P-value of 0.05 in order to detect the main metabolites that were significantly different in leading to the class discrimination[63].

Bacterial DNA extraction

Each digesta sample was processed individually for DNA extraction and each individual DNA sample was used for subsequent analyses of pyrosequencing and qPCR assays. Bacterial DNA was extracted using QIAamp DNA Stool Mini Kit (Qiagen, Valencia, CA, USA) in accordance with the manufacturer’s instructions. Briefly, approximate 0.2 g of digesta sample was lysed by incubation at 95 °C in Buffer ASL. PCR inhibitors and DNA-degrading substances were adsorbed to InhibitEX. Proteins were digested by incubation with Proteinase K at 70 °C. DNA was bound to the QIAamp silica-gel membrane and impurities were washed away. Purified DNA was eluted from the QIAamp spin column. The extracted bacterial DNA was stored at −80 °C until further analysis.

DNA Pyrosequencing

Each individual digesta DNA sample was used to generate two PCR amplicon libraries that were combined for pyrosequencing. The PCR primers (universal to eubacteria) 28 F (5′-GAGTTTGATCNTGGCTCAG-3′) and 519 R (5′-GTNTTACNGCGGCKGCTG-3′) targeting the V1-V3 region of 16S rRNA genes were used to generate the amplicon libraries. Because of the insufficient sensitivity of eubacterial primers to Bifidobacterium 16S rRNA genes[18,19], primers Bif-xfp-2294-F (5′-GAYGAGACCGCKTCCAACC-3′) and Bif-xfp-2691-R (5′-GAAGCCGTTGTGRTCCTGACG-3′), which target the 5-phosphate⁄fructose-6-phosphate phosphoketolase (xfp) gene of Bifidobacterium, were employed to produce amplicon libraries for pyrosequencing[20,21]. Pyrosequencing primers included the sequencing primer and an 8-nucleotide barcode. Amplicon libraries for the 16S rRNA gene and xfp gene were generated and analyzed separately. Bacterial tag-encoded FLX amplicon pyrosequencing was performed with Titanium on a Roche 454 FLX sequencer by the Research and Testing Laboratory in Lubbock (Texas, USA).

Quantitative PCR assays

The qPCR assays were used to determine the relative abundance of genus Bifidobacterium and some bacterial groups relating to butyrate production, including Clostridial clusters IV and XIVa and bacteria harboring the gene of butyryl-CoA:acetate CoA transferase[22]. The assays were performed with individual digesta DNA samples separately using a S1000 Thermocycler (1852148, Bio-Rad Laboratories, Hercules, CA, USA). The following was the thermal cycle profile: 95 °C for 3 min; 40 cycles of 95 °C for 15 sec, a specific annealing temperature for 30 sec, and 72 °C for 30 sec. A thermal melt curve was generated by heating at 95 °C for 1 min, 55 °C for 30 sec, and ramping back to 95 °C in 0.5 °C increments. The 25-μl reaction mixture contained 1.0 μl of DNA template, 12.5 μl of 2× iTaq SYBR Green Supermix (Bio-Rad, Hercules, CA, USA), and forward and reverse primers (Table S1). The abundance of the different groups of bacteria was normalized using the amplicon from the universal PCR primers towards eubacteria[64], which served as an internal housekeeping control. Fold changes in the abundance of different group bacteria were calculated by the 2−∆∆Ct method[65]. The PCR primers were those used for Bifidobacterium[20], Butyryl-CoA:acetate CoA transferase[66], Colostridial cluster IV[67], and Colostridial cluster XIVa[68,69], respectively (Table S1).

Bioinformatics and statistical analysis of microbiota

The data generated from each sample (either pyrosequencing or qPCR assays) were analyzed separately before combination for the analysis of treatment effects. Raw sequence data were denoised using the software USEARCH[70]. Detection and removal of chimeras were performed using the software UCHIIME[71]. Sequences with low quality and less than 250 bp in length were removed. Sequences passing the quality control screening were processed by the Quantitative Insights Into Microbial Ecology (QIIME) pipeline (http://qiime.sourceforge.net). Barcode and primers were removed during the demultiplexing step. The sequences were grouped into OTUs at least 97% similarity using UCLUST. For the 16S rRNA gene, a representative sequence was picked from each OTU and assigned taxonomy using the Ribosomal Database Project (RDP) naïve Bayesian classifier[72] with the confidence threshold as 80%. The sequences were aligned against the Greengenes-imputed core reference alignment using PyNAST, and the concatenated alignment of OTU was filtered to remove gaps and hypervariable regions using the Greengenes Lane mask. The filtered sequences alignment was then used to build a phylogenetic tree for calculation of UniFrac diversity. Data were rarefied to the lowest counts of sequences per sample for calculation of alpha and beta diversities. The PCoA based on the unweighted UniFrac distance was implemented in the software QIIME. For the sequences of the xfp gene, taxonomic assignments of the OTUs were made by comparison to a reference database of the xfp gene[21,73]. The ANOSIM provides a way to test whether similarities within groups are higher than those between groups, thus allowing for testing whether bacterial communities were different between two or more groups[74]. This nonparametric test was implemented in R package vegan (version 2.0–4), and UniFrac distance was used as a measure of dissimilarity of bacterial communities in the ileal or cecal digesta[75]. When the ANOSIM test indicated a difference of bacterial communities between the control and BG-treated group, SPLS-DA was utilized to select OTUs that could be used for separation of the two groups using the R package spls[76,77]. Sparse partial least squares regression can achieve variable selection and dimension reduction simultaneously. For our data, the binary response was the dietary treatment, i.e. 6 birds were selected from each of the control and BG-treated group. The relative abundance of OTUs was normalized as percentage of total number of sequences for an individual bird and related to the corresponding dietary treatment. A heat map of the relative abundance of selected OTUs in the cecal digesta was created by the R package gplots. Relative abundances of taxonomy and OTU were compared between the control and BG-treated group using a permutation test via online software Metastats[17]. The qPCR data were subjected to simple t-test[78]. Significance level was set at 0.05.
  68 in total

Review 1.  Metabolomics and its potential for assessment of adequacy and safety of amino acid intake.

Authors:  Yasushi Noguchi; Ryosei Sakai; Takeshi Kimura
Journal:  J Nutr       Date:  2003-06       Impact factor: 4.798

Review 2.  Host-gut microbiota metabolic interactions.

Authors:  Jeremy K Nicholson; Elaine Holmes; James Kinross; Remy Burcelin; Glenn Gibson; Wei Jia; Sven Pettersson
Journal:  Science       Date:  2012-06-06       Impact factor: 47.728

3.  Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells.

Authors:  Yukihiro Furusawa; Yuuki Obata; Shinji Fukuda; Takaho A Endo; Gaku Nakato; Daisuke Takahashi; Yumiko Nakanishi; Chikako Uetake; Keiko Kato; Tamotsu Kato; Masumi Takahashi; Noriko N Fukuda; Shinnosuke Murakami; Eiji Miyauchi; Shingo Hino; Koji Atarashi; Satoshi Onawa; Yumiko Fujimura; Trevor Lockett; Julie M Clarke; David L Topping; Masaru Tomita; Shohei Hori; Osamu Ohara; Tatsuya Morita; Haruhiko Koseki; Jun Kikuchi; Kenya Honda; Koji Hase; Hiroshi Ohno
Journal:  Nature       Date:  2013-11-13       Impact factor: 49.962

4.  Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces.

Authors:  Takahiro Matsuki; Koichi Watanabe; Junji Fujimoto; Yukiko Miyamoto; Toshihiko Takada; Kazumasa Matsumoto; Hiroshi Oyaizu; Ryuichiro Tanaka
Journal:  Appl Environ Microbiol       Date:  2002-11       Impact factor: 4.792

5.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.

Authors:  Marc-Emmanuel Dumas; Richard H Barton; Ayo Toye; Olivier Cloarec; Christine Blancher; Alice Rothwell; Jane Fearnside; Roger Tatoud; Véronique Blanc; John C Lindon; Steve C Mitchell; Elaine Holmes; Mark I McCarthy; James Scott; Dominique Gauguier; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

6.  Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers.

Authors:  Luying Peng; Zhong-Rong Li; Robert S Green; Ian R Holzman; Jing Lin
Journal:  J Nutr       Date:  2009-07-22       Impact factor: 4.798

7.  Utilization of nutrients by isolated epithelial cells of the rat colon.

Authors:  W E Roediger
Journal:  Gastroenterology       Date:  1982-08       Impact factor: 22.682

8.  Development of the human infant intestinal microbiota.

Authors:  Chana Palmer; Elisabeth M Bik; Daniel B DiGiulio; David A Relman; Patrick O Brown
Journal:  PLoS Biol       Date:  2007-06-26       Impact factor: 8.029

9.  Effects of orally applied butyrate bolus on histone acetylation and cytochrome P450 enzyme activity in the liver of chicken - a randomized controlled trial.

Authors:  Gábor Mátis; Zsuzsanna Neogrády; György Csikó; Anna Kulcsár; Akos Kenéz; Korinna Huber
Journal:  Nutr Metab (Lond)       Date:  2013-01-22       Impact factor: 4.169

10.  Statistical methods for detecting differentially abundant features in clinical metagenomic samples.

Authors:  James Robert White; Niranjan Nagarajan; Mihai Pop
Journal:  PLoS Comput Biol       Date:  2009-04-10       Impact factor: 4.475

View more
  8 in total

1.  Effects of monobutyrin supplementation on egg production, biochemical indexes, and gut microbiota of broiler breeders.

Authors:  Xin Feng; Fangang Kong; Liwei Zheng; Qien Qi; Lina Long; Li Gong; Weilong Huang; Huihua Zhang
Journal:  Poult Sci       Date:  2020-12-10       Impact factor: 3.352

2.  Impact of Dietary Sodium Butyrate and Salinomycin on Performance and Intestinal Microbiota in a Broiler Gut Leakage Model.

Authors:  Mohammad Naghizadeh; Laura Klaver; Anna A Schönherz; Sundas Rani; Tina Sørensen Dalgaard; Ricarda Margarete Engberg
Journal:  Animals (Basel)       Date:  2022-01-04       Impact factor: 2.752

3.  Chemically Protected Sodium Butyrate Improves Growth Performance and Early Development and Function of Small Intestine in Broilers as One Effective Substitute for Antibiotics.

Authors:  Huaibao Zhao; Hai Bai; Fuli Deng; Ruqing Zhong; Lei Liu; Liang Chen; Hongfu Zhang
Journal:  Antibiotics (Basel)       Date:  2022-01-20

4.  Alterations in Intestinal Antioxidant and Immune Function and Cecal Microbiota of Laying Hens Fed on Coated Sodium Butyrate Supplemented Diets.

Authors:  Sasa Miao; Zuopeng Hong; Huafeng Jian; Qianqian Xu; Yating Liu; Xiaoming Wang; Yan Li; Xinyang Dong; Xiaoting Zou
Journal:  Animals (Basel)       Date:  2022-02-22       Impact factor: 2.752

Review 5.  New insights into natural products that target the gut microbiota: Effects on the prevention and treatment of colorectal cancer.

Authors:  Lu Lu; Jiahuan Dong; Yujing Liu; Yufan Qian; Guangtao Zhang; Wenjun Zhou; Aiguang Zhao; Guang Ji; Hanchen Xu
Journal:  Front Pharmacol       Date:  2022-08-15       Impact factor: 5.988

6.  Effect of a specific composition of short- and medium-chain fatty acid 1-Monoglycerides on growth performances and gut microbiota of gilthead sea bream (Sparus aurata).

Authors:  Simona Rimoldi; Emi Gliozheni; Chiara Ascione; Elisabetta Gini; Genciana Terova
Journal:  PeerJ       Date:  2018-07-31       Impact factor: 2.984

7.  Research Note: Effect of butyric acid glycerol esters on ileal and cecal mucosal and luminal microbiota in chickens challenged with Eimeria maxima.

Authors:  Monika Proszkowiec-Weglarz; Katarzyna B Miska; Lori L Schreier; Christopher J Grim; Karen G Jarvis; Jonathan Shao; Stefan Vaessen; Richard Sygall; Mark C Jenkins; Stanislaw Kahl; Beverly Russell
Journal:  Poult Sci       Date:  2020-07-03       Impact factor: 3.352

8.  Flaxseed Oil and Heated Flaxseed Supplements Have Different Effects on Lipid Deposition and Ileal Microbiota in Albas Cashmere Goats.

Authors:  Shulin Liu; Xue Wang; Yinhao Li; Binlin Shi; Xiaoyu Guo; Yanli Zhao; Sumei Yan
Journal:  Animals (Basel)       Date:  2021-03-12       Impact factor: 2.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.